OPEN END TURBO LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 19:24:35 05/06/2024 BST | ||
| 0.93 EUR | +6.90% |
|
| Current month | -25.00% | ||
| 1 month | -7.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.93 | +6.90% |
| 04/06/24 | 0.87 | -33.59% |
| 03/06/24 | 1.31 | +5.65% |
| 31/05/24 | 1.24 | +30.53% |
| 30/05/24 | 0.95 | +1.06% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 07:24 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1YMK |
| ISIN | DE000MG1YMK9 |
| Date issued | 09/04/2024 |
| Strike | 557.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.64 € |
|---|---|
| Lowest since issue | 0.34 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat